SynAct Pharma to present at 19th World Congress of Basic and Clinical Pharmacology in Glasgow on July 4

SynAct Pharma AB (publ) (“SynAct”) today announced that Chief Scientific Officer Thomas Jonassen will present at the upcoming 19th World Congress of Basic and Clinical Pharmacology (WCP 2023) conference in Glasgow, Scotland, hosted by The British Pharmacological Society. Jonassen will speak on July 4 between 9:45am to 12:10pm as part of a symposium titled “Resolution Pharmacology – new therapeutic approaches for the treatment of inflammatory diseases.”

Resolution therapy aims to help the body restore immune balance and proper function in situations like autoimmune diseases where inflammation has become dysregulated and chronic. Dr. Jonassen will present Phase 2a data from SynAct’s BEGIN trial of its lead asset resomelagon (AP1189), a biased melanocortin receptor agonist selective for the type 1 and 3 melanocortin receptors that is in Phase 2 clinical development for rheumatoid arthritis (RA). Resomelagon is currently in two additional Phase 2 trials in RA that will read out later this year.

“Speaking at WCP 2023 is a great opportunity for SynAct to talk to the medical community and other key stakeholders about resomelagon. Clinical study data from both the EXPAND and RESOLVE phase 2 RA studies are due in the second half of this year making this an ideal time to talk about the potential to treat RA with resolution therapy. Resolution therapy could offer a new approach to treating chronic inflammatory diseases by modulating the immune system without causing immunosuppression which can lead to significant safety issues and present limitations to the use of currently available therapies,” said Thomas Jonassen, CSO of SynAct.

For further information, please contact:
Torbjørn Bjerke, CEO
Phone: +46 727 44 41 58
Mail: [email protected]
Mail: [email protected]

Thomas Jonassen, CSO
Phone: +45 40 15 66 69
Mail: [email protected]

About SynAct Pharma
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: